Method for preparing largazole analogs and uses thereof
Analogs of largazole are described herein. Methods of treating cancer and blood disorders using largazole and largazole analogs and pharmaceutical compositions comprising the same are additionally described herein. Methods for preparing largazole analogs are likewise described.
1. A compound of Formula (I)
wherein X is S or O;
Y is NR or O, wherein R is H, lower alkyl, or lower arylalkyl;
Z is S or O; wherein at least one of X and Z is O;
R 1 is H, lower alkyl, or lower arylalkyl;
R 2 is lower alkyl, isopropyl, n-propyl, cyclopropyl, isobutyl, n-butyl, sec-butyl, or tert-butyl;
R 4 is H, (CH 2 ) n COOH, (CH 2 ) n CONHR, (CH 2 ) n CONHOH, (CH 2 ) n SR 3 , SR 5 (wherein R 5 is lower alkyl or lower aryl),
wherein n is at least 1, and wherein R 3 is H, octanoyl, acyl, SR, a higher acyl derivative, or
or a pharmaceutically acceptable salt, prodrug, or stereoisomer thereof.
2. The compound of claim 1 ,
wherein X is S or O;
Y is NH or O;
Z is S or O; wherein at least one of X and Z is O;
R 1 is H or methyl;
R 2 is lower alkyl or isopropyl;
R 4 is H, (CH 2 ) n COOH, (CH 2 ) n CONHR, (CH 2 ) n CONHOH, (CH 2 ) n SR 3 ,
wherein n is at least 1, and wherein R 3 is H, octanoyl, acyl, SR, a higher acyl derivative, or
or a pharmaceutically acceptable salt, prodrug, or stereoisomer thereof.
3. The compound of claim 1 , having the Formula (VII)
or a pharmaceutically acceptable salt, prodrug, or stereoisomer thereof.
4. The compound of claim 1 , having the Formula (IX)
or a pharmaceutically acceptable salt, prodrug, or stereoisomer thereof.
5. A pharmaceutical composition comprising a therapeutically effective amount of the compound of claim 1 and at least one pharmaceutically acceptable excipient for treating cancer in a subject.
6. A pharmaceutical composition comprising a therapeutically effective amount of a compound of Formula (I)
wherein X is S or O;
Y is NR or O, wherein R is H, lower alkyl, or lower arylalkyl;
Z is S or O; wherein at least one of X and Z is O;
R 1 is H, lower alkyl, or lower arylalkyl;
R 2 is lower alkyl, isopropyl, n-propyl, cyclopropyl, isobutyl, n-butyl, sec-butyl, or tert-butyl;
R 4 is H, (CH 2 ) n COOH, (CH 2 ) n CONHR, (CH 2 ) n CONHOH, (CH 2 ) n SR 3 , SR 5 (wherein R 5 is lower alkyl or lower aryl),
wherein n is at least 1, and wherein R 3 is H, octanoyl, acyl, SR, a higher acyl derivative, or
or a pharmaceutically acceptable salt, prodrug, or stereoisomer thereof; and at least one pharmaceutically acceptable excipient for treating a blood disorder in a subject.
7. A pharmaceutical composition comprising a therapeutically effective amount of the compound of claim 1 and at least one pharmaceutically acceptable excipient for treating a blood disorder in a subject, wherein the blood disorder is at least one of a hemoglobinopathy or a thalassemia.
8. The pharmaceutical composition of claim 5 or 6 , wherein the subject is human.
9. A composition comprising a radiolabelled compound of Formula (I)
wherein X is S or O;
Y is NR or O, wherein R is H, lower alkyl, or lower arylalkyl;
Z is S or O; wherein at least one of X and Z is O;
R 1 is H, lower alkyl, or lower arylalkyl;
R 2 is lower alkyl, isopropyl, n-propyl, cyclopropyl, isobutyl, n-butyl, sec-butyl, or tert-butyl;
R 4 is H, (CH 2 ) n COOH, (CH 2 ) n CONHR, (CH 2 ) n CONHOH, (CH 2 ) n SR 3 , SR 5 (wherein R 5 is lower alkyl or lower aryl),
wherein n is at least 1, and wherein R 3 is H, octanoyl, acyl, SR, a higher acyl derivative, or
or a pharmaceutically acceptable salt, prodrug, or stereoisomer thereof.